



IBW

Page 1 of 3

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re application : Mats Hellström et al.
Serial No. : 10/581,761
Filed : April 10, 2008
For : ANGIOGENESIS AFFECTING POLYPEPTIDES,
PROTEINS AND COMPOSITIONS, AND METHODS
OF USE THEREOF
Examiner :
Attorney Docket : 102959-202
Group Art Unit :
Confirmation No. : 6588
Customer No. : 27267

I hereby certify that this correspondence is being deposited with the United States Postal Service, First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 09 APR 2009

By Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.56, the Examiner is respectfully requested to consider the references cited on attached Form PTO-1449. A copy of each reference (if not previously submitted) is enclosed. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- [X] 1. This Information Disclosure Statement is being filed within three months of the U. S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U. S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. Each item of information contained on Form PTO/SB/08a and/or 08b filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1); and no fee is required under 37 C.F.R. §1.17(p).
- ☐ b. No item of information cited on Form PTO/SB/08a and/or 08b filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2); and no fee is required under 37 C.F.R. §1.17(p).
- ☐ Please charge Deposit Account No. 23-1665 in the amount of \$180.00 in payment of the fee under 37 C.F.R. §1.17(p). Two additional copies of this Information Disclosure Statement are enclosed.
- ☐ A check in the amount of \$180.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered.
- ☐ a. Each item of information contained on Form PTO/SB/08a and/or 08b filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).

- ☐ b. No item of information cited on Form PTO/SB/08a and/or 08b filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- ☐ Please charge Deposit Account No. 23-1665 in the amount of \$180.00 in payment of the fee under 37 C.F.R. §1.17(i)(1). Two additional copies of this Information Disclosure Statement are enclosed.
- ☐ A check in the amount of \$180.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(i)(1).

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Respectfully submitted,

MATS HELLSTRÖM ET AL.

Date: 09 APR 2009

By: Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicants

WIGGIN AND DANA LLP
One Century Tower
New Haven, CT 06508-1832
Telephone : (203) 498-4400
Facsimile: (203) 782-2889



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Mats Hellström et al.
Serial No. : 10/581,761
Filed : April 10, 2008
For : ANGIOGENESIS AFFECTING POLYPEPTIDES,
PROTEINS AND COMPOSITIONS, AND METHODS
OF USE THEREOF

Examiner :
Attorney Docket : 102959-202
Group Art Unit :
Confirmation No. : 6588
Customer No. : 27267

I hereby certify that this correspondence is being deposited with the United States Postal Service, First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 09 APR 2009.

By

Todd E. Garabedian

Todd E. Garabedian, Ph.D.

Registration No. 39,197

Attorney for Applicants

INFORMATION DISCLOSURE LETTER

Mail Stop Amendment
Commissioner for Patents
U. S. Patent and Trademark Office
Washington, D.C. 20231

Sir:

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

1. United States Patent No. 6,242,179 B1 (SHAH, PURVI ET AL.) 5 June 2001 (2001-06-05).
2. United States Patent No. 5,602,307 (BEAUDET, ARTHUR L. ET AL.) 11 February 1997 (1997-02-11).
3. United States Patent No. 5,489,743 (ROBINSON, MURRAY O. ET AL.) 6 February 1996 (1997-02-06).

4. United States Patent Application Publication No. 2003/0203843 A1 (PENA, CAROL E. A. ET AL.) 30 October 2003 (2003-10-30).
5. United States Patent Application Publication No. 2003/0100497 A1 (BAKER, KEVIN P. ET AL.) 29 May 2003 (2003-05-29).
6. International Patent Application No. WO 2003/079982 A2 (LI, JING ET AL.) 2 October 2003 (2003-10-02).
7. International Patent Application No. WO 2003/072827 A1 (HIRSCH, RAPHAEL, ET AL.) 4 September 2003 (2003-09-04).
8. International Patent Application No. WO 2003/046578 A2 (CHIBOUT, SALAH-DINE ET AL.) 5 June 2003 (2003-06-05).
9. International Patent Application No. WO 2003/026403 A2 (WISOTZKEY, ROBERT G. ET AL.) 3 April 2003 (2003-04-03).
10. International Patent Application No. WO 2002/094780 A2 (YUE, HENRY ET AL.) 28 November 2002 (2002-11-28).
11. International Patent Application No. WO 2002/079492 A2 (MURRAY, RICHARD ET AL.) 10 October 2002 (2002-10-10).
12. International Patent Application No. WO 1998/46830 A1 (VALTANEN, JARKKO) 22 October 1998 (1998-10-22).
13. European Patent Application No. EP 1 347 059 A1 (LÜBBERT, HERMANN ET AL.) 24 September 2003 (2003-09-24).
14. European Patent Application No. EP 1 114 862 A1 (WOLF, ECKARD ET AL.) 11 July 2001 (2001-07-11). This European Patent Application discloses use of a polypeptide or its variant (I) or nucleic acid encoding (I) or its variant for the diagnosis and/or prevention and/or treatment of skin disorders and/or treatment in wound healing or for the identification of pharmacologically active substances. This patent also discloses use of a polypeptide or its variant (I) or nucleic acid encoding (I) or its variant for the diagnosis and/or prevention and/or treatment of skin disorders and/or treatment in wound healing or for the identification of pharmacologically active substances.
15. BOHLING, FRANK ET AL., *"Cathepsins K, L, B, X and W are differentially expressed in normal and chronically inflamed gastric mucosa"*, BIOLOGICAL CHEMISTRY, Vol. 385, Pages 439-445 (2004).

16. TIGYI, GABOR JOSEPH ET AL., "*Multiple phenotypic abnormalities in lipid phosphate phosphatase-1 transgenic mice without alteration in lysophosphatidate level and signaling*", FASEB JOURNAL, Vol. 17, No. 405, Abstract No. 123.7 (2003).
17. SMYTH, SUSAN S. ET AL., "*Lipid phosphate phosphatases regulate lysophosphatidic acid production and signaling in platelets. Studies using chemical inhibitors of lipid phosphate phosphatase activity*", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 278, No. 44, Pages 43214-43223 (2003).
18. TANYI J. L. ET AL., "*Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer*", CLINICAL CANCER RESEARCH, Vol. 9, No. 101, Pages 3534-3545 (2003).
19. SONG, ZHI-QIANG ET AL., "*Analysis and screening of differentially expression genes of dermal papillae cells with aggregative behavior*", ZHONGHUA PIFUKE ZAZHI", Vol. 36, No. 9, Pages 513-515 (September, 2003).
20. SHIN, JORDAN T. ET AL., "*From zebrafish to humans: Modular medical models*", ANNU. REV. GENOMICS AND HUMAN GENETICS, Vol. 3, Pages 311-340 (June 12, 2002).
21. CLARK, MATTHEW D. ET AL., "*An oligonucleotide fingerprint normalized and expressed sequence tag characterized zebrafish library*", GENOME RESEARCH, Vol. 11, No. 9, Pages 1564-1602 (September 2001).
22. NASEVICIUS, AIDAS ET AL., "*Effective targeted gene 'knockdown' in zebrafish*", NATURE GENETICS, Vol. 26 (October 2000).
23. DEUSSING, JAN ET AL., "*Murine and human cathepsin Z: cDNA-cloning, characterization of the genes and chromosomal localization*", BIOCHIMICA ET BIOPHYSICA ACTA, Vol. 1491, Pages 93-106 (2000).
24. BOUKHELIFA M. ET AL., "*Palladin, a novel cytoskeleton associated protein involved in neural maturation*", SOCIETY FOR NEUROSCIENCE ABSTRACTS, Vol. 26, No. 1-2, Abstract No. 314.7 (2000).
25. ZHU, ZHENPING ET AL., "*Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor*", INVESTIGATIONAL NEW DRUGS, Vol. 17, Pages 195-212 (1999).
26. KAI, MASAHIRO ET AL., "*Cloning and characterization of two human isozymes of Mg²⁺ independent phosphatidic acid phosphatases*", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 272, No. 38, Pages 24572-24578 (1997).

27. KAI, MASAHIRO ET AL., "*Identification and CDNA cloning of 35-KDA phosphatidic acid phosphatase (type2) bound to plasma membranes*", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 271, No. 31, Pages 18931-18938 (1996).
28. INNIS, Michael A. ET AL., "*Optimization of PCRs - PCR Protocols, A Guide to Methods and Applications*", ACADEMIC PRESS, INC. (1990).
29. Database EPO Proteins (online) Accession No. CQ896404, HINZMANN, B. ET AL., "*Human nucleic acid sequences obtained from prostatic carcinomas*", 5 November 2004 (2004-11-05).
30. Database EMBL (online) Accession No. CG597335, ZAMBROWICZ, B. P. ET AL., "*Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention*", 8 October 2003 (2003-10-08).
31. Database EMBL (online) Accession No. CD541309, PIAO, Y. ET AL., "*Construction of long-transcript enriched cDNA libraries from submicrogram amounts of total RNAs by a universal PCR amplification method*", 12 June 2003 (2003-06-12).
32. Database EMBL (online) Accession No. AK088577, ADACHI, J. ET AL., "*The transcriptional landscape of the mammalian genome*," 19 December 2002 (2002-12-19).
33. Database EMBL (online) Accession No. AX140435, WOLF, E. ET AL., "*Use of polypeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in identifying pharmacologically active substances*", 31 May 2001 (2001-05-31).
34. Database EMBL (online) Accession No. AF136273, DEUSSING, J ET AL., "*Murine and human cathepsin Z: cDNA-cloning, characterization of the genes and chromosomal localization*", 26 November 1999 (1999-11-26).
35. Database EMBL (online) Accession No. AB000888, KAI, M. ET AL., "*Cloning and characterization of two human isozymes of Mg²⁺-independent phosphatidic acid phosphatase*", 7 October 1997 (1997-10-07).

Applicants submit that copies of the above-cited references are enclosed herewith.

If the Examiner has any questions or feels that a discussion with Applicants' representative would expedite prosecution, the Examiner is invited and encouraged to contact Applicants' undersigned representative at the telephone number listed below.

Respectfully submitted,

MATS HELLSTRÖM ET AL.

Date: 09 APR 2009

By: Todd E. Garabedian

Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant(s)

WIGGIN AND DANA LLP
One Century Tower
P. O. Box 1832
New Haven, CT 06508-1832
Telephone: (203) 498-4400
Facsimile: (203) 782-2889

151693\2194052.1